Summit Therapeutics Plans Interim PFS Analysis for HARMONi-3 Squamous Cohort

Summit Therapeutics announced plans to conduct an interim progression-free survival (PFS) analysis for its HARMONi-3 squamous cohort in the second quarter of 2026, as the company continues to expand its clinical pipeline.